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The Biopharmaceutics Classification System (BCS), developed in the 1990s for oral immediate release drugs, is
utilized by R&D scientists and regulators to streamline product development and regulatory approval timelines. This
elegant, science-based approach is based on three in vitro parameters representing a combination of drug
substance physicochemical and physiological properties with respect to oral administration; specifically a dose
number, dissolution number, and absorption number. Interest in applying similar principles to pulmonary drug
products is increasing. To date the focus has been on dissolution of drugs in the lung. A workshop co-sponsored
by the AAPS, FDA, and USP was held in March 2015 in Baltimore to evaluate if a systematic framework to classify
pulmonary drugs could be established, and the scope and relevance of such a classification scheme. The focus of
the workshop was to address factors influencing drug delivery and action in the lungs rather than the development
of a specific model or system. Presentations included: the history and evolution of the oral BCS (described as the
“giBCS” by Gordon Amidon), lung physiology and the fate of inhaled drugs, regional aerosol deposition and dose,
macroscopic clearance mechanisms, particle dissolution, drug permeability, absorption and their interplay with
pharmacokinetics and pharmacodynamics. Background discussions were followed by three separate breakout
sessions each focused on the BCS concepts of dose, dissolution, and absorption numbers as they would apply to
pulmonary drug delivery. The workshop concluded that a classification system, if fully developed, would be a useful
tool for formulators and discovery chemists. The scope of such a system, at this point in time, would not include
aspects relevant to regulatory relief. The goals of the workshop were met by identifying an opportunity to develop
a model to classify pulmonary drugs based on physicochemical attributes specific to lung physiology and drug
delivery.
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The workshop was opened by Jayne Hastedt (JDP
Pharma Consulting, USA) who challenged attendees
to think about how differences in location and con-
ditions in the lungs vs GI might affect efficacy and
safety of drugs delivered to those locations and how
better knowledge of those factors might lead to more
facile development of new pulmonary pharmaceuti-
cals. The following is a summary of that commen-
tary which included a presentation by Gordon
Amidon (University of Michigan, USA) on the devel-
opment of the giBCS some 20 years ago.
The systemic absorption and distribution of a drug
substance from a dosage form is dependent primarily
upon the physicochemical properties of the drug, the
dose administered, and the permeability and pharma-
cokinetics associated with the route of administra-
tion. An approach to classify orally administered
drugs based on a macroscopic assessment of gastro-
intestinal permeability and aqueous solubility was
first introduced in the 1990s (Amidon et al. 1995).
Even though this Biopharmaceutical Classification
System (giBCS) has been revised over the ensuing
years, the goal has remained the same. The giBCS
model for orally administered drugs provides a basis
for correlating in vitro drug product dissolution to
in vivo bioavailability assuming that drug dissolution,
drug dose, and GI permeability are the attributes dic-
tating the rate and extent of drug absorption via the oral
route of administration (USDHHS/FDA 2015).
In contrast, drugs delivered via inhalation are typic-
ally not intended for systemic administration. Inhaled
drugs, classically designed to treat diseases of the
lung, are deposited within the complex and diverse
architecture of that organ. Instead of swallowing the
dosage form to deliver a dose of active drug to the
GI for absorption and distribution, inhaled drugs are
administered using an inhalation device that delivers
a nominal dose. The inhalation delivery route adds
the complications that drug deposition within the
lung and the dose to the lung are primarily influ-
enced by the inhalation device design, aerodynamic
particle size and distribution of the dispersed product,
fluid mechanics, and the way the patient interacts
with the drug delivery device. Although an inhalation
drug classification system has not been established to
date, at least one paper has been published on this
topic (Eixarch et al. 2010). For inhaled drug products,
development of a classification system that combines
the physicochemical properties of the drug, the crit-
ical quality attributes of the product, and the biology
of the lung is the first step in understanding the role
of in vitro performance parameters as they affect
in vivo product performance.In order to assess whether or not a biopharma-
ceutical characterization approach can be developed
for inhaled drugs, appropriate biorelevant properties
of pulmonary drugs (e.g., solubility, dissolution, per-
meability) need to be identified. This would be
followed by a thorough study of the relationship be-
tween the biopharmaceutical properties and the
unique physiological attributes of the target organ,
and in this case, the lung and the distinctive attri-
butes of the pulmonary product. These parameters
include: retention time in the lung, the amount and
type of “fluid” available for dissolution, physiology of
the various regions of the lung, lung dose, and de-
position patterns.
A characterization system based on the biopharma-
ceutical properties of inhaled drugs was explored at the
Inhalation Biopharmaceutical Product Classification Sys-
tem Development: Challenges and Opportunities work-
shop held in March 2015 in Baltimore1. The workshop
was co-sponsored by the AAPS, FDA, and USP. The
goal of the workshop was to investigate whether or not
development of a classification system based on physio-
logically relevant physicochemical properties of pulmon-
ary drugs could prove beneficial to the development of
inhaled drug products. The giBCS approach was used as a
starting point for the workshop discussions. The following
topical areas were explored as refinements to address the
differences/similarities between the GI and the lung:
 Lung permeability and transport
 The role of fluid mechanics in pulmonary drug
deposition
 Particle dissolution in the lung and in vitro testing
as applicable to lung particle dissolution
 PK/PD modeling for lung delivery.
Fifty-four senior level pharmaceutical scientists, en-
gineers and physicists, clinical pharmacokineticists,
toxicologists, regulators, and academicians working in
the inhalation field attended the workshop. Attendees
were drawn from 15 US states plus 7 foreign coun-
tries and included 9 representatives from government
agencies, 10 from academia, and 35 from industry, in-
cluding contract pharma representatives. After 2 days
of deliberation attendees agreed that a classification
system for inhaled drug products would be beneficial
to formulators and drug discovery chemists. Therefore
efforts to identify attributes similar to the giBCS ap-
proach (e.g., dose number, dissolution number, and
absorption number) for inhaled drug products will be
one of the next steps in this effort. All attendees
agreed that any attempt to relate these attributes to
bioequivalence of inhaled drug products was beyond
the scope of the current effort.
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sentations and the overall conclusions and next steps
identified during the workshop.
Discussion
Lung physiology and the fate of inhaled drugs
Before proceeding to the factors influencing the delivery,
dissolution and disposition of aerosol particles delivered
to the lungs, the environment in which they will deposit
must be described sufficiently for the later consideration.
The topics considered in the following section describe
the structure and function of the lungs and regions
within it from a macroscopic, organ system, anatomical,
and microscopic, composite-cell scale to help frame later
discussion of the interactions of drugs with the various
interfaces that govern bioavailability and efficacy. ThisFig. 1 Pulmonary drug deliverysection reflects presentation materials provided by
Pete Mauser (Merck R&D, USA), Claus-Michael Lehr,
(Saarland University, Germany), and Ralph Niven (Novartis,
USA) during the workshop.
Basic physiology of the respiratory tract
The lungs (Fig. 1) are a complex organ system designed
to enable the efficient exchange of gases between the
blood and the respiratory airspace. The fact that the
lungs have developed sophisticated, multi-tiered de-
fenses directed to removing particulate and soluble ma-
terial that would not normally be resident in the
airspaces presents an ongoing challenge for inhalation
therapies (Albertine 2010; Olsson et al. 2011).
Functionally, the lungs can be thought of as having
two distinct zones. The first is composed of a tubular
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the external environment and the second is a respiratory
zone where gas exchange takes place. The tracheobron-
chial tree bifurcates repeatedly creating up to 23 divi-
sions before reaching the alveoli (16 divisions in the
‘transport’ or ‘conducting’ zone and another 7 within the
respiratory zone) (Table 1) (Hickey & Thompson 1992;
Moffet et al. 1993; Weibel 1963).
With each division of the tracheobronchial tree there
is a reduction in diameter of the bronchi, a shortening
of their length, an increase in their number and a con-
comitant increase in the surface area (Hickey & Thomp-
son 1992; Moffet et al. 1993; Weibel 1963).
Pulmonary defense mechanisms
The conducting zone possesses a number of mecha-
nisms that protect the lungs:
1. Anatomically, the repeated branching presents a
defensive ‘sifting’ zone to ‘trap’ particles via inertial
impaction and sedimentation while allowing inhaled
gases to be humidified and warmed to body
temperature.
2. A gel/sol lining fluid with ciliated epithelium
captures particles deposited on the airways and
transports them via the mucociliary escalator to the
oropharynx whereupon they are swallowed.
3. Beneath this lining fluid is a highly responsive airway
epithelium intimately associated with a variety of
cells of the innate and adaptive immune systemTable 1 A schematic representation of airway branching in the hum4. A variety of neuronally-linked receptors (e.g. lung ir-
ritant receptors (LIR) and C fibers) that can induce
mechanical clearance mechanisms, such as cough,
changes in breathing pattern and bronchial tone in
response to particles and dissolved mediators.
The respiratory zone is made up of functional units
(some 15,000 or so in the lungs (Hansen & Ampaya
1974)). Each unit consists of a terminal bronchiole, a re-
spiratory bronchiole, alveolar ducts and alveolar sacs:
collectively referred to as the acinus. Because airflow vel-
ocity decreases from 150 cm/s in the upper conducting
airways to nearly zero in the peripheral airways, move-
ment of both particles and gases is via mass-action or
diffusion within the acinus and is primarily concentration-
driven. Particles that deposit and persist in this environ-
ment will be dispersed or cleared by surfactant and phago-
cytic cells.
Cellular barriers and mechanisms of clearance
As shown in Fig. 2, the cellular morphology of the
pulmonary mucosa along the respiratory tract changes
significantly, in parallel with its physiological function.
In the conducting airways, the cells are columnar-
shaped and ciliated. This cell morphology transitions
to a cuboidal form deeper in the respiratory tree and
eventually takes on a squamous configuration in the
alveoli. Two prominent cell types (epithelial type I
(ET-1) and II (ET-II) cells) can be distinguished in
the alveoli. Although the ET-II cells dominate inan lung
Fig. 2 Throughout the respiratory tract, the cell type and morphology changes in concert with their physiological function (Hittinger et al. 2015),
adapted from (Klein et al. 2011)
Hastedt et al. AAPS Open  (2016) 2:1 Page 5 of 20terms of number (about 70–90 %), the ET-I cells
cover 90 + % of the surface area and are therefore the
major cell type forming the ‘air-blood-barrier’ of the
lungs. The combination of a large alveolar surface
area (>100 m2) and small diffusion distances between
blood and airspaces (~1 um), facilitate effective pul-
monary gaseous exchange.
Pulmonary surfactant is a complex lipoprotein mixture
that, among other functions, helps maintain the patency
of the airspaces during inhalation maneuvers. Within
the alveoli, the overall lining layer has a harmonic mean
thickness of < 0.2 μm but the depth can vary significantly
in alveolar pockets. The surfactant may strongly influ-
ence the dispersion of drugs depositing on the alveolarTable 2 Characteristic Cell Numbers and Lung Values
Parameter Value
Alveolar Surface Area 143
# of alveoli (adult lung) 250+
# of type I pneumocytes 1.9
# of type II pneumocytes 3.7
# of resident macrophages 2.3
Depth of airway fluid 5–10
Harmonic mean depth of alveolar fluid 0.2
Diameter of an alveolus 200–250surface depending upon the physicochemical character-
istics of the agent.
The primary, resident phagocytic cell is the alveolar
macrophage (MØ). It is estimated that over 2.3 billion
of these cells are present throughout the lungs in a
healthy individual and some 1–3 of these cells may
be present at various locations within each alveolus
(Table 2). Particles in the alveolus activate type 1 epi-
thelial responses, which in turn attract MØ activity
through chemokine release and other signaling path-
ways. MØs and other phagocytic cells (e.g., neutro-
phils and T-cells) can rapidly be recruited to the
airspaces in response to signals from the pneumocytes
or other sources.Unit Reference
m2 (Gehr et al. 1978)
Million (Crapo et al. 1982)
Billion (Crapo et al. 1982)
Billion (Crapo et al. 1982)
Billion (Crapo et al. 1982)
um (Widdicombe 2002)
um (Bastacky et al. 1995)
um (Parent 1982)
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of slow enzymatic disposal, transport along the alveolar
surface to the mucociliary escalator and/or translocation
to the interstitium and tracheobronchial lymphatic
capillaries.
Mucus and surfactant as a non-cellular barrier
The pulmonary barrier is also comprised of import-
ant extracellular elements. Any particulate matter
deposited in the conducting airways will be removed
relatively quickly with a half-life of approximately 1
to 1.5 h by the “mucocillary escalator” (Agnew et al.
1986). Mucus is a natural glycoprotein-hydrogel and
has some unique structural and rheological features
that enable it to trap particles while also acting as a
diffusional barrier for dissolved solutes. The continu-
ous transport of mucus toward the proximal trachea
and esophagus limits any accumulation of particles
within the conducting airways. Within the alveoli,
pulmonary surfactant forms a monolayer on the al-
veolar lining fluid. It consists predominantly of phos-
pholipids, but also some specific surfactant proteins,
referred to as SP-A,-B,-C, and –D. Surfactant pro-
teins B and C are primarily associated with the sur-
face tension lowering properties of the surfactant
while A and D are involved in host-defense. Surfac-
tant also contributes to clearance of particles from
the lungs via dispersion and adsorption. The inter-
action of nanoparticles with the alveolar lining fluid
leads to the formation of a peculiar “corona” around
the nanoparticles, which in turns mediates theirFig. 3 Cellular and non-cellular barriers of the lung: after landing on lung lining
reach the underlying tissue or the systemic circulation, respectively, and must al
and the clearance by macrophage in the deep lung (de Souza et al. 2014), Modinteraction with cells. The two scenarios that parti-
cles may encounter after deposition in either the
bronchial or alveolar part of the lungs, respectively,
are summarized in Fig. 3. The composition, approxi-
mate layer thickness, and approximate total layer
volumes for upper airway mucus and alveolar surfac-
tant are summarized in Table 3.
Drug transport and metabolism
Drugs or solutes that ‘survive’ and reach the epithelial
surface can be removed from the airspaces by transloca-
tion across the epithelium. This may occur via a number
of recognized, but poorly understood, mechanisms,
some of which are shown in Fig. 4. It should be noted
that these mechanisms also exist in the alveolus.
Drugs may be metabolized when transported via air-
way epithelial cells, Clara cells or via metabolically-
active type II pneumocytes. Bio-active agents may also
be degraded by a host of membrane-bound, secreted or
shed enzymes released from a variety of sources.
Our knowledge about specific transporter systems, as
well as efflux pumps and metabolizing enzymes in the
lungs is currently still in its infancy, although there is
evidence of transporters in context of pulmonary drug
absorption and delivery (Patton et al. 2010). Another im-
portant consideration for inhalation drug delivery is fluid
transport. Fluid levels are tightly-controlled in the lungs
but through manipulation of channels such as eNaC and
Aquaporin, micro-focal changes in fluid depth can read-
ily be enacted and thus influence the solubility and dis-
persion of particles on the apical surface.fluids (1) the drug must cross the pulmonary epithelium (2) in order to
so overcome clearance processes (3) mucociliary clearance in the airways
ified with permission from (Ruge et al. 2013)
Table 3 Composition of lung lining fluid in conducting airways and respiratory zone (from (Eixarch et al. 2010) and (Hastedt 2014))
Conducting airways Respiratory Zone
Principal lining fluid Mucus Surfactant
Composition of fluid layer 1 % inorganic salts 85 % phospholipids
1 % proteins 5 % cholesterol
2 % glycoproteins (mucins) 10 % surfactant proteins (e.g., SP-A, SP-B, SP-C, SP-D)
1 % lipids
95 % water
Layer thickness 3–15 μm (decreases in thickness in lower airways) ~0.07 μm
Approximate volume 10–30 ml 7–20 ml
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We see that there are some important differences to
be considered if a characterization system such as the
giBCS is to be applied to inhaled drugs. Fundamen-
tally, the role of the gut is to accept foreign material
for processing, uptake and expulsion. In contrast, the
lungs are designed to remove foreign material in
order to maintain gas exchange. They act more like a
selective “sieve” or a “leaky bucket” than a “tube”,
which necessitated evolution of a variety of effective
clearance mechanisms since the lung cannot rely on
‘flow-through’ or transit processes, as in the case of
the digestive tract. While at a cellular level the gen-
eral mechanisms of uptake and absorption are prob-
ably quite similar to those understood for the gut, at
the macro level the lungs are quite different having a
larger surface area and generally much shorter
exchange-distances. Further, a highly variable milieu
exists in the gut as a function of location and food
intake. So, in general, diffusion into the blood/lymphFig. 4 Transport pathways for drugs across an epithelial barrier (Kolaca et al. 19
lipophilic molecules), (2.) paracellular diffusion (for hydrophilic molecules and de
peptides and proteins) (3) active transport via specific receptors and “pumps” (4
metabolism by epithelial cellsare governed by the concentration gradient, particle/
molecule size, its charge, lipophilicity and of course
the membrane properties of the absorptive surface. In
the next section we take a closer look at the practical
aspects of drug deposition into and clearance from
the lungs.Deposition and clearance
Andy Clark (Aerogen Pharma, USA), who described
the fluid mechanics behind pulmonary drug depos-
ition, began by showing that the airways can be
broken down into three compartments based upon
the fate of deposited materials. In the mouth and oro-
pharynx, insoluble materials are swallowed. In the
central or conducting airways insoluble materials are
cleared by the mucocilliary escalator and are eventu-
ally swallowed. In the peripheral airways insoluble
materials are cleared by phagocytosis and/or other
cellular clearance mechanisms (Clark et al. 2006).96). (1) passive transcellular diffusion (probably for most small, sufficiently
pending on the integrity of intercellular junctions, also a pathway for
) vesicular transport (endo-transcytosis) (5) efflux to the apical side and/or
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of these compartments to differing extents and, de-
pending upon their physico-chemical properties, may
be absorbed into the systemic circulation. However,
the extent to which the resultant systemic exposure
and pharmacokinetics contribute to efficacy depends
upon the desired site of action for the molecule. For
molecules intended to act systemically using the lung
as a portal of entry into the circulatory system, ab-
sorption and resulting systemic levels are obviously
extremely important. But for locally-acting com-
pounds, where the intended site of action is in the
lung tissue itself, systemic levels are actually only a
measure of the drug that has passed through the
lung tissue and is no longer available at the site of
action. Similarly, where the site of action is in the
airspace in the lung, such as inhaled antibiotics, sys-
temic drug levels reflect drug that is no longer avail-
able to contribute to reducing or eliminating
bacterial load. Thus, while systemic drug levels and
pharmacokinetics may be useful to indicate extent of
absorption and duration of absorption from the lungFig. 5 A schematic diagram of the two compartment “Tube and Bucket” m
clearance and absorption, the peripheral lung only experiences absorptionthey are not necessarily a measure of efficacy for
locally-acting drugs.
From a biopharmaceutical classification perspective,
drugs reaching and depositing within the lung will ex-
perience the latter of these two environments. Soluble
drugs, where dissolution and absorption are rapid
compared to mucocillary clearance rates, will be
absorbed from the lung almost completely with a
lung bioavailability of approximately 1. However, the
absorption of insoluble or sparingly soluble drugs, or
those drugs that are absorbed slowly, will be affected
by the regional deposition pattern within the lung.
Drug deposited in the central airways will experience
a competition between clearance from the lung via
the mucocillary escalator and dissolution and subse-
quent absorption though the lung epithelium.
Whereas drug deposited in the peripheral lung essen-
tially has “no way out” other than through absorption
and cellular clearance mechanisms. Thus, the bioavail-
ability of insoluble or slowly absorbed drugs will gen-
erally be less than one and will depend upon the
regional deposition pattern. In the extreme the lungodel of lung clearance and absorption. The central airways experience
. (As suggested by Hastedt 2014)
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in the peripheral airways. Figure 5 presents a simple
diagram of this “tube and bucket” (Hastedt 2014)
model of the lower airways illustrating the two com-
partments and the competing clearance and absorp-
tion mechanisms in each.
Absorption of poorly soluble, slowly absorbed mole-
cules can obviously result in a complete lack of correl-
ation between the total dose deposited in the lung and
the resulting systemic exposure. This is illustrated in
Fig. 6 for a poorly soluble selective glucocorticoid modu-
lator, where total lung dose, predicted using a mouth/
throat model, is compared to observed AUC values in
healthy volunteers (Olsson & Bäckman 2014). The au-
thors explain this lack of correlation as due to differ-
ences in initial regional deposition leading to variability
in the fraction cleared from the central airways during
absorption.
Deposition in the airways is controlled by three fac-
tors; airway geometry, aerodynamic particle size, and in-
haled flow rate (Lippman 1977). Smaller particle sizes
and lower flow rates result in higher lung deposition by
avoiding deposition in the mouth and oropharynx and in
general result in larger fractions of the lung dose depos-
iting in the peripheral airways (Task Group on Lung Dy-
namics 1966; Stahlhofen et al. 1980). It should be noted
here that for pharmaceutical inhalers, where a deep in-
spiration and breath hold are employed, less than 1 or
2% of the inhaled dose is usually exhaled (Clark 2010).
Thus, with a few notable exceptions (Qvar and some for-
mulations used in the Respimat) it is quite reasonable toFig. 6 A comparison of the systemic exposure (AUC) of a poorly
soluble selective glucocorticoid modulator (SGRM) and the predicted
total lung dose for six different devices and formulations (number of
healthy volunteers ranging between 12 and 18). (From (Olsson &
Bäckman 2014))assume that whatever gets into the lung deposits in the
lung.
Figure 7 illustrates the range of drug masses deposited
in the lung from various inhaler technologies and drug
classes. The figure was constructed using published de-
position data obtained from a variety of scintigraphy
studies (Clark 2015) by taking the nominal dose for each
particular product and multiplying it by the fraction de-
posited in the lung as determined from the gamma cam-
era images. Two observations can be made. The first is
with regard to the dosing capability of each technology,
Soft Mist Inhalers can deliver up to ~100 μg to the lung,
pressurized Metered Dose Inhalers up to ~800 μg, Dry
Powder Inhalers up to 10 mg and finally nebulizers
which in principle can deliver several hundred milli-
grams to lung depending on drug solubility and the ac-
ceptability of long nebulization times. The second
observation, particularly relevant here, is the lung dose
by drug class. Highly potent β2 agonists and anticholin-
ergics represent the lowest lung doses and inhaled anti-
biotics the highest, with the lung dose obviously being a
manifestation of the potency of drug being inhaled. The
overall concentration of drug in the lung, assuming in-
stantaneous dissolution and a fluid volume of 50 mL
(Clark et al. 2006), thus ranges from 1 μg/mL to 6 or
8 mg/mL depending up on the drug.
However, this is an average concentration and the ac-
tual concentrations will vary by location both due to
variation in fluid volume in different generations of the
airways and due to regional deposition patterns of the
deposited drug. Figure 8 (Clark 2012) illustrates the re-
gional deposition patterns obtained with various drug
products using different inhaler technologies. The data
were derived from scintigraphy studies using peripheral
to central “regions of interest” (Newman et al. 1998) and
calibrations correlating the P/C ratios to 24 h clearance
using insoluble radiolabeled markers (for more details
see (Clark 2012)). It can be seen from the figure, by
comparing the P/C ratio for pulmonary products with
the 24-h retention values from the calibration, that the
fraction of the total lung dose deposited in the periphery
varies from around 0.4 to 0.6. While this might seem a
rather small range it should be remembered that the in-
haled aerosol entering the trachea, and thus reaching the
lung, has been “prefiltered” by the mouth and orophar-
ynx and does not have as broad or as variable size distri-
bution as that initially generated by the inhaler device.
This rather narrow range is a manifestation of the inter-
action between the capture efficiency of the mouth and
oropharynx and that of the conducting airways.
In order to put these lung doses and regional depos-
ition patterns into perspective it is useful to refer again
to Fig. 5. Remembering that for highly soluble and rap-
idly absorbed molecules the lung dose and regional
Fig. 7 A summary of the lung doses achieved with the major inhalation delivery technologies and drug classes as determined by gamma
scintigraphy. (From (Clark 2015))
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ability, which will essentially be close to 1 when deter-
mined on the basis of total lung dose. For very insoluble
drugs or poorly absorbed molecules the systemic bio-
availability will be equal to that fraction of the dose de-
posited in the peripheral region of the lung, or on
average approximately 50 %.
However, it is worth mentioning again that absorp-
tion and availability in the systemic circulation is not
necessarily an indicator of presence or duration of ac-
tion at a receptor. Rather it is a measure of drug that
has passed through the lung and is no longer present
to exert a local effect. In this regard the efficacy pic-
ture is much more complex than that provided by
looking only at deposition, clearance and absorption
and great care needs to be taken in interpreting clear-
ance, dissolution, absorption and systemic levels in
terms of the efficacy of locally acting drugs. Once de-
position of drug particles has occurred, the next
phenomenon to be considered is the dissolution of
those particles. In the following section, we undertake
a more detailed consideration this event.Particle dissolution
Jeff Weers (Novartis, USA) provided the basic princi-
ples to be considered for particle dissolution in the
lungs beginning with how Amidon et al. began their
classic paper on biopharmaceutical drug classification
with the following statement: “Drug dissolution is a
prerequisite to drug absorption and clinical response
for almost all drugs given orally” (Amidon et al.
1995). This statement is also true for drugs adminis-
tered via oral inhalation (Hastedt 2014). Amidon
et al. (Amidon et al. 1995) derived two dimensionless
numbers (i.e., the dose number, Do and the Dissol-
ution Number, Dn) that were used to assess drug dis-
solution. The Dose Number, Do, provides a measure
of the impact of drug solubility on dissolution, vis:
Do ¼ M0=V 0
Cs
ð1Þ
Where M0 is the dose, V0 is the volume of dissolution
fluid, and Cs is the drug solubility. For orally adminis-
tered drugs, V0 is assumed to be the initial gastric
Fig. 8 Regional lung deposition for the major inhalation delivery
system as assessed by gamma scintigraphy / penetration index and
24 h clearance measurements. The theory line was calculated using
the model proposed by Stahlhofen (Stahlhofen et al. 1980),
diameters given on theory line are Mass Median Aerodynamic
Diameters for aerosols of a Geometric Standard Deviation of 2.2.
(From (Clark 2012))
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impacted by ‘targeted’ delivery of drug to the site of ac-
tion, which lowers M0, and by the smaller volume of li-
quid lining the lungs. This is often assumed to be on the
order of 10–30 mL in the conducting airways. Figure 9
is a plot of solubility vs. dose in the conducting airways,
Dc for a range of pulmonary drugs. There is a band run-
ning through the plot which represents the criticalFig. 9 Solubility of pulmonary drugs vs. the required dose in the conductinsolubility for V0 = 10–30 mL, wherein drugs above this
band have sufficient solubility to be dissolved (i.e., Do <
<1.0), and drugs below the band are dissolution limited
(Do> > 1). Most of the currently marketed small mol-
ecule drugs for inhalation, including short-acting and
long-acting bronchodilators and tobramycin, are not dis-
solution limited. For these drugs, the extent of absorp-
tion is approximately 1.0, and is not limited by particle
dissolution or permeability. As a rule of thumb, lipo-
philic drugs with a log P > 0 are rapidly absorbed via the
transcellular route with an absorption time of ca., 1 min.
In contrast, hydrophilic drugs with a log P < 0 are
absorbed via the paracellular route with an absorption
time of ca., 1 h (Patton et al. 2004).
In contrast, there are two main classes of drugs that
are dissolution limited. For potent inhaled corticoste-
roids with a nominal dose less than 1 mg, dissolution
becomes important when drug solubility is <1 μg/mL
(e.g., fluticasone propionate, mometasone furoate, and
beclomethasone dipropionate). As well, high dose
antiinfectives with a nominal dose > 1 mg, become
dissolution limited when the solubility <100 μg/mL
(e.g., ciprofloxacin betaine, amphotericin B). That is,
in the lungs, dissolution limited drugs meet the
standard definition of being ‘insoluble’ (Merck Index
definition of insoluble is < 100 μg/mL). The impact of
inhaled corticosteroid solubility on mean dissolution
time was studied by Högger et al. (Högger et al.
1994) (Table 4). Corticosteroids with a solubility on
the order of 0.1 μg/mL and >10 exhibit significant in-
creases in mean dissolution time relative to drugs
with greater solubility and Do <1. Similarly, Forbes
et al. (Forbes et al. 2015) noted a clear correlation be-
tween solubility and mean absorption time in man for
these compounds.g airways
Table 4 Impact of solubility on mean dissolution time of
inhaled corticosteroids
Drug CS (μg/ml) Do Mean Dissolution
Time (hr)




Budesonide 16 0.375 ~0.1
Flunisolide 140 0.01 <0.03
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drug absorption into the systemic circulation is
dependent on the pattern of regional deposition in the
lungs. Relative to healthy volunteers, patients with ob-
structive lung disease will have a more central distribu-
tion of drug within the lungs. This results in increased
mucociliary clearance and decreased systemic bioavail-
ability (Brutsche et al. 2000). The observed dependence
of regional deposition and systemic absorption on par-
ticle clearance makes establishing IVIVC via in vitro dis-
solution testing challenging for dissolution-limited
drugs.
The rate of particle dissolution is related to Amidon’s
Dissolution Number, Dn (Amidon et al. 1995). Dn is
given by:
Dn ¼ tres⋅3DC=ρr20 ð2Þ
Where tres is the mean residence time, D is the diffu-
sion coefficient, ρ = particle density, and r0 is the particle
radius. For oral drugs, r0 is assumed to be 25 μm. In
contrast, pulmonary drugs must have a r0 < 2.5 μm in
order to achieve effective delivery as an aerosol into the
lungs. The ten-fold decrease in size results in 100-fold
increases in Dn. The impact of particle size on dissol-
ution and resulting absorption rate and subsequent peak
plasma concentration (Cmax) can be illustrated by the 2-
fold increase in peak plasma concentration (Cmax) ob-
served for a poorly soluble selective glucocorticoid
modulator (SGRM) as primary particle size decreased
from 3.1 μm to 1.3 μm (Olsson & Bäckman 2014). Sig-
nificant increases in Dn for pulmonary drugs are also
observed, especially for formulations comprising spray-
dried or spray-freeze dried particles, as a result of de-
creases in particle density and/or increases in ‘apparent’
solubility when an amorphous physical form is created
(Duddu et al. 2002; Almeida e Sousa et al. 2015; Weers &
Tarara 2014). For example, large increases in surface area
can be achieved via control of particle morphology (i.e.,
creating nanostructured micron-sized particles) (Duddu
et al. 2002; Weers & Tarara 2014). The converse is also
possible. Decreases in particle dissolution can be
achieved by utilization of the neutral or zwitterionicform of a drug with decreased solubility. In this re-
gard, ciprofloxacin HCl has a lung half-life in rats of
0.8 h following intratracheal administration, while the
zwitterionic form at neutral pH has a decreased solubility
and a half-life of 13.5 h (Endermann et al. 2011). The in-
creased lung residence time results in significant reduc-
tions in colony forming units of Pseudomonas aeruginosa
in the lungs of these animals.
Particle dissolution in the lung: In vitro
dissolution testing
The basic principles of particle dissolution in the lungs
was followed by Jason McConville (University of New
Mexico, USA) explaining that in vitro dissolution testing
for powders formulated for lung application will more
than likely differ from procedures applied for dissolution
testing of oral formulations and therefore will still only
approximate the in vivo situation. For example, when
one considers the complex dissolution environment of
the GI tract is not completely reflected in the standard-
ized conditions that are used for in vitro testing of
pharmaceutical products in the laboratory. Dissolution
of inhalation powders is potentially a critical component
of the iBCS puzzle, and so standardized test method-
ology should be carefully considered. Figure 10 com-
pares some factors considered for the dissolution of oral
products compared to those necessary for inhaled prod-
ucts, assuming sink conditions. Note that it is antici-
pated that the dissolution rate of poorly water soluble
compounds delivered to the lung will mainly be import-
ant in the peripheral regions of the lung and not in the
central regions.
A principle method development consideration must
be how to reproducibly present the particles to the dis-
solution test apparatus. There are some specific prob-
lems related to inhalation powders that are of concern
(e.g., aggregation due to electrostatic interactions).
Table 5 summarizes some of the areas of concern for
dissolution in the lungs vs. in the GI tract.
Published approaches for aerosol particle dissolution
When dissolution is used as a research tool it is import-
ant to reflect on the goal of the test. Before any type of
IVIVC can be considered it must be realized that the
dissolution test is used to make a comparison between
formulations under standardized conditions. As such,
any test must be sufficiently reproducible so as to pro-
vide confidence in the results. With this in mind, a test
should also be easy to set up and easy to use.
Multiple methods have been applied in an attempt to
create a reproducible dissolution test for dispersed pow-
der systems (Barakat et al. 2015; Davies & Feddah 2003;
Jaspart et al. 2007; May et al. 2014; May et al. 2012;
McConville et al. 2000; Riley et al. 2012; Son et al. 2010;
Fig. 10 The fate of oral vs. inhaled drug products in the body
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method (McConville et al. 2000), the first to employ the
use of an impactor/impinger, describes dispersing pow-
der onto an air-liquid interface and evaluating drug dis-
solution into a specially designed dissolution reservoir.
The apparatus comprised a modified twin stage liquid
impinger with an enlarged Stage 1 base. Powder that
was above the specified 4.7 μm particle cut-off impinged
on an air-water interface, and dissolution of salbutamol
from controlled release formulations was evaluated using
a flow through detector. The method described was sim-
ply used for formulation comparison and was not de-
signed to ‘mimic’ any conditions of the lung, and as
described, the large particle sizes were only assessed
leaving the <4.7 μm fraction to be evaluated only as a
fine particle mass. Salama et al. describe a similar
method that makes use of a modified Franz diffusion ap-
paratus incorporating a heated membrane holder at its
surface and a heated dissolution reservoir containing
phosphate buffered saline at pH 7.4. Drug formulations
can be placed onto a membrane before inserting into the
membrane holder, in this way an air-liquid interface is
maintained as drug diffuses into the reservoir for ana-
lysis (Salama et al. 2008).Table 5 Considerations for different organ target sites
GI Tract Considerations
SA of dose important (for disintegration)
Large SA for absorption
High Liquid volume
pH 1–8
Rel. High hydrodynamic conditionsDavies and Feddah (Davies & Feddah 2003) presented
a method that utilized a flow through dissolution ap-
proach after impaction of an aerosol powder onto a fil-
ter. In this approach the authors made use of an NGI
apparatus and positioned a filter at the base of the USP
throat. Powder collected on the filter was then sealed
into flow-through holder. An HPLC pump was used to
flow dissolution media through the filter until the entire
drug had been removed for analysis, allowing for the
construction of a cumulative release dissolution profile.
This technique again made use of the oversized powder
fraction, but in this case it was dispersed with the fine
powder fraction.
Jaspart (Jaspart et al. 2007) described a method where
powder was sealed within a filter membrane and
immersed within the basket of a Type I dissolution ap-
paratus. This method demonstrates some issues related
to the contact area of a powder and as such is most
likely suited to high solubility drug products.
A recent method also made use of the NGI apparatus
by collecting powder dispersed into each collection stage
either onto a polycarbonate membrane (Son & McCon-
ville 2009), or directly onto the stainless steel collection
base (Son et al. 2010). With either powder collectionLung Considerations
Dose has large SA
Large SA for dissolution/abs.
Low liquid volume
pH 6–7
Rel. Low hydrodynamic conditions
Macrophage interaction
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covered with a large pore polycarbonate membrane and
placed in its own Type II dissolution apparatus vessel
(either large volume or small volume). The dissolution
media could be collected at intervals in the normal way
and analyzed to construct a dissolution profile. The lat-
ter method adopting the use of the stainless steel impac-
tion base demonstrated the most reproducible method
for the Type II apparatus to date.
Overall, standard dissolution methods can be adapted
for a variety of formulation types, and previous studies
have shown that dosage form presentation to the dissol-
ution method chosen is a key component in determining
reproducibility. Reproducibility for comparative pur-
poses is critical for both R&D and quality control. Once
there is an established methodology to address this
shortfall, then IVIVC studies may follow.
Additionally, although a dissolution method may be
designed to reasonably represent actual particle dissol-
ution on a representative airway mucosa, it is still un-
clear if we must take into consideration the balance
between dissolution and absorption and how this
changes from the very permeable peripheral regions of
the lung to the less permeable conductive airways.
Hence, it is possible that non-sink conditions encoun-
tered in the conductive airway means observed
dissolution-related changes are unrelated to, for ex-
ample, peak plasma concentration.. Thus, to understand
the clinical relevance of an in vitro dissolution profile we
must understand deposition pattern, particle clearance,
local permeability, tissue sequestration and absorption
into the systemic circulation.
Permeability, absorption and PK/PD in the lung
Following deposition and dissolution in the lung, aerosol
drugs are absorbed through the pulmonary membrane
barriers primarily by diffusion and possibly via trans-
porters (Patton et al. 2004; Sakagami & Gumbleton
2011). Masahiro Sakagami (Virginia Commonwealth
University, USA) presented this session and the sum-
mary provided includes commentary from Guenther
Hochhaus (University of Florida, USA) and Per Bäckman
(AstraZeneca, Sweden). For dissolved low molecular
weight drugs, the intrinsic lung absorption rates are gen-
erally fast with absorption half-lives of ≤ 1 h, irrespective
of lipophilicity or involvement of transporters. Excep-
tions to this generalized behavior arise when there is
sustained binding to, or slow dissociation from, the lung
membrane components including target proteins (e.g.,
LABAs and LAMAs), or intracellular trapping (e.g., fatty
acid esterification and basic amines) (Patton et al. 2004;
Sakagami & Gumbleton 2011; Anderson et al. 1994;
Casarosa et al. 2009; Edsbäcker & Brattsand 2002; Lasic
et al. 1995). These intrinsic kinetic properties of lungabsorption/permeability can be reasonably studied using
in vitro lung epithelial cell monolayer systems, such as
Calu-3 cells (Forbes & Ehrhardt 2005; Mathia et al.
2002), in a manner similar to how the Caco-2 cell sys-
tem is utilized for classification of intestinal absorption.
Permeability values are well-correlated with the in vivo
rate constants (ka) for lung absorption in animals (For-
bes & Ehrhardt 2005; Mathia et al. 2002), which likely
makes them useful in rank-ordering and screening drugs
with respect to their intrinsic lung absorption rates. Even
so, deriving inhalation BCS class boundaries to classify
high or low lung absorption/permeability from these
in vitro lung epithelial cell systems would not be simple.
In vivo ka values are time-dependent and thus, it is likely
that the observed initial ka values largely reflect rapid
absorption from the peripheral lung. Ideally, an iBCS
model for absorption/permeability should be predictive
for the region of clinical interest, yet is in reality a chal-
lenge, given that this is poorly defined in most cases and
that absorption from the more central regions of the
lung cannot be easily determined. To further complicate
the situation, in the lung, absorptive elimination is in
kinetic competition with non-absorptive elimination,
mainly by mucociliary clearance from the upper regions
of the lung, as illustrated in Fig. 11 (Olsson & Bäckman
2014). Hence, the performance of inhaled drugs, such as
local therapeutic lung effects and systemic adverse
events, depends not only on these intrinsic absorp-
tion/permeability properties but also on aerosol for-
mulation/device, delivery and drug dissolution
properties in determination of their PK/PD profiles.
In addition, it should be noted that lung targeting
may also be improved by high systemic (hepatic)
clearance and low oral bioavailability, which both re-
duce the degree of systemic exposure (Tayab & Hoch-
haus 2005; Weber & Hochhaus 2013).
The competitive nature of lung disposition was
clinically seen, when beclomethasone dipropionate
(BDP) was reformulated from a CFC to a HFA
metered dose inhaler (MDI) product (Leach et al.
1998). Smaller-size aerosol delivery from the HFA-
based solution MDI was capable of greater lung per-
ipheral deposition and local PD effects, compared to
the CFC-based suspension MDI (Leach et al. 1998).
Likewise, as described in an earlier section, a poorly
soluble and highly permeable, selective glucocortic-
oid receptor modulator (SGRM) demonstrated more
than a 2-fold change in PK profiles (Cmax and AUC)
in humans following inhaled delivery from different
dry powder inhalers and nebulizers. This was attrib-
uted by the authors to be a result of differences in
dissolution rate and regional lung deposition (Leach
et al. 1998). Therefore, during preclinical develop-
ment of inhaled drugs, it is not surprising that both
Fig. 11 Lung disposition of pharmaceutical aerosol drugs following inhalation. MCC: mucociliary clearance. Adapted from (Olsson &
Bäckman 2014)
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and drug dissolution-controlled PK properties must
be considered to optimize a drug’s local or systemic
PD effects (e.g., potency and duration of effect). In
this context, lung disposition in animals like rats
and dogs, but perhaps not mice, rabbits and guinea
pigs are often kinetically equivalent to that in
humans (Patton et al. 2004; Sakagami & Gumbleton
2011), especially for highly soluble and well absorbed
low molecular weight drugs. In fact, Ferguson (Fer-
guson 2010) reported that the lung absorption ka
values for such drugs like terbutaline and roflepo-
nide in rats and dogs enabled prediction of the PK
profiles in humans with a reasonable degree of con-
fidence, assuming their complete lung absorption.
Moreover, with a given pulmonary administration,
animal models are also capable of assessing “drug in
formulation” effects on PK/PD outcomes such as
local lung PD actions via receptor binding and occu-
pancy determination (Suarez et al. 1998; Talton et al.
2000). However, aerosol delivery has commonly re-
sulted in greater lung absorption and local/systemic
PD effects in animals, compared to forced lung dos-
ing methods like instillation (Brown & Schanker
1983; Niven et al. 1995). Thus, regional lung depos-
ition control is essential in animal studies, yet its
relevance to PK/PD outcomes for aerosol drugs gen-
erated from inhaler devices in humans still remains
to be established.
Compartmental PK/PD modeling simulations can be
very helpful to better understand the complex interplay
of deposition, clearance, dissolution and absorption. For
instance, it has been suggested that factors increasing
the lung residence time, such as slow dissolution, low
permeability/slow absorption, and intracellular trapping,
increase pulmonary targeting of drugs following inhal-
ation (Tayab & Hochhaus 2005; Weber & Hochhaus
2013). In addition, as mucociliary clearance functions
only in the upper regions of the lung, an optimal dissol-
ution rate to maximize such pulmonary targeting wasalso identified (Tayab & Hochhaus 2005; Weber &
Hochhaus 2013). Given these notions, more realistic
compartmental lung disposition kinetic models have
been recently developed for poorly soluble corticoste-
roids, incorporating regional lung (i.e., central and per-
ipheral) deposition, dissolution rate-controlled
absorption and mucociliary clearance (Tayab & Hoch-
haus 2005; Sakagami 2014; Weber & Hochhaus 2015).
The models resulted in plausible successes in fitting/
simulating and describing different PK profiles of poorly
soluble fluticasone propionate (FP) formulated in various
inhaler products, while yielding its lung region-
independent, dissolution-controlled slow absorption rate
with a half-life of ~3.5 h (Tayab & Hochhaus 2005; Saka-
gami 2014; Weber & Hochhaus 2015). In line with these
results, a further study has now implied that in vitro-
based mean dissolution times may be an indicator for
the in vivo lung absorption rates of slowly-dissolving,
lipophilic corticosteroids (e.g., FP, ciclesonide and bude-
sonide) (Rohrschneider et al. 2015). Meanwhile, PK-
linked systemic PD modeling was found feasible for in-
haled FP to predict the profiles of serum cortisol reduc-
tion, as potential systemic adverse outcomes (Meibohm
et al. 1999; Möllmann et al. 1998). However, PK-linked
local PD modeling remains theoretical for inhaled
corticosteroids in humans, due to a lack of appropri-
ate measurable local PD markers, as have been also
the cases for inhaled bronchodilators (Gaz et al. 2012;
Hochhaus et al. 1997).
Mechanistic computer-based modeling may also be
used to provide better understanding on how deposition,
dissolution, clearance, absorption and systemic dispos-
ition influence the clinical performance of an inhaled
product. In a recent example, a mechanistic model was
applied to predict systemic exposure following inhaled
administration of SGRM in healthy volunteers using six
different devices and formulation. Initial data show sys-
temic exposure to be well predicted, as shown in Fig. 12
(Olsson & Bäckman 2014), in contrast to the poor cor-
relation between systemic exposure and predicted lung
Fig. 12 Observed and predicted systemic exposure (AUC) following
inhaled administration of SGRM using six different devices and
formulations (12–18 healthy volunteers). The dashed line represents
the identity line. Modified from (Olsson & Bäckman 2014)
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sults has also demonstrated that the shape of the plasma
PK profile was well predicted, thereby providing useful
insights into the fate of the drug deposited in different
lung regions [AstraZeneca, data on file].
Case studies
Following the presentation of background information,
three case studies were presented to provide some pos-
sible food for thought as to where having an iBCS might
take us, at least with respect local therapy. Bäckman pre-
sented clinical PK data and mechanistic modeling data
on a selective glucocorticoid modulator Hochhaus pre-
sented some thoughts on how this might work for an
ICS, and Niven extended the discussion to atypical mol-
ecules. The following summarizes those discussions.
Clinical PK data comparing systemic exposure of a
lipophilic selective glucocorticoid receptor modulator in
healthy volunteers after administration in six different
inhalation formulations and devices was shown to cor-
relate better with peripheral lung dose than with total
lung dose or total delivered dose. Also, the rate and ex-
tent of absorption from lung after inhalation was shown
to be well predicted by deposition pattern in combin-
ation with the expected rate of mucociliary clearance
and rate of dissolution in situ as simulated by a com-
puter based mechanistic model. Taken together these
observations indicate: (i) that the bioavailability of this
compound depends on intra pulmonary deposition pat-
tern and; (ii) that dissolution is the rate limiting step
governing the systemic absorption rate for this lipophilic
drug. Given that solubility of inhaled glucocorticoids is
related to mean absorption time in man (May et al.2014), this observation can probably be generalized to
all inhaled drugs with low water solubility, as discussed
above. Hence, it is concluded that rate of dissolution is
an important predictor of clinical performance for this
class of compounds and that a BCS type of classification
could provide an important aid to both compound and
product design, if qualified by dose and regional depos-
ition pattern.
When taking an analogy to the giBCS model (Varma
et al. 2004) lung absorption/permeation properties for
inhaled drugs/products can be potentially classified with
the absorption number (An), which can be defined as
the ratio of mean residence time to mean absorption
time in the lung. However, both of these temporal pa-
rameters are lung region-dependent and thus, should
ideally be determined for the region(s) of clinical inter-
est, which is difficult, as we currently lack appropriate
experimental methods to make this assessment. Besides,
in the giBCS model, mean residence time is fixed at
180 min, yet its definition and value in the lung are un-
certain. Even so, for locally-acting drugs, it is notable to
recognize that many recent successes appear to arise out
of deviation from giBCS Class I characteristics, i.e., slow
dissolution (e.g., FP and ciclesonide) and slow intrinsic
permeation/absorption through sustained binding or
intracellular trapping (e.g., LABAs, LAMAs, budesonide,
and possibly, tiotropium and olodaterol) (Anderson et al.
1994; Casarosa et al. 2009; Edsbäcker & Brattsand 2002;
Lasic et al. 1995; Borghardt et al. 2014; Parra-Guillen
et al. 2014). This suggests that slow dissolution rate and
low absorption numbers are favorable for locally-acting
low molecular weight drugs, as this combination pro-
vides sufficient lung retention to achieve the desired
local pharmacological effects without rapid absorption/
disappearance from the lung. The implementation of an
iBCS approach may therefore facilitate engineering such
properties into the development pipeline.
Conclusions
Historically, the lungs have offered a unique opportunity
to target drugs for local action and more recently have
been considered a potential route for systemic delivery.
Biopharmaceutical factors influencing drug disposition
and efficacy have been known generally for several de-
cades. However, a systematic framework describing the
contribution of each of the elements of the drug and de-
livery system physical chemistry, lung physiology, anat-
omy, cell biology, biophysics and biochemistry to
performance has been an elusive objective.
This workshop was held to determine if a systematic
framework to classify pulmonary drugs could be estab-
lished, and if so, what the scope and relevance of such a
classification approach would be. Considerations were:
lung physiology and the fate of inhaled drugs, regional
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particle dissolution, drug permeability and absorption.
The interplay of these attributes on pharmacokinetics
and pharmacodynamics was also discussed.
The giBCS was established when solubility and perme-
ability of drug was shown to be predictive of bioavail-
ability and efficacy. In contrast drugs of importance for
lung delivery are subject to a series of rate constants not
only at the microscopic scale but also at the macroscopic
scale of clearance mechanisms. Whereas the GI accepts
foreign materials for further processing, the lungs
have a defense mechanism that is designed to reject
or removes foreign materials in order to preserve gas
exchange. Therefore, the lungs present a series of bar-
riers to the entry of aerosol particles and droplets
that the GI does not.
For particles small enough to enter the lung, at the
macroscopic level, the branching airways act in syn-
chrony with inspiratory airflow to facilitate airborne par-
ticulate capture regionally. Mucociliary clearance and
cell mediated transport and absorption determine the
fate of inhaled drugs. In the central airways, the main
clearance mechanism is mucociliary clearance, while in
the periphery clearance is governed by macrophage up-
take and permeability/systemic absorption rates. Drug
deposition, and therefore the dose to the various regions
within the lung, is controlled by airway geometry, aero-
dynamic particle size distribution and inhaled flow rate.
The overall concentration of drug in the lung is there-
fore dynamic and varies by region due to differences in
“fluid” levels and clearance mechanisms. Peripheral de-
position is on the order of 50 % of the total lung dose.
As indicated, the residence time of drug deposited in
different locations in the lungs depends upon the pre-
dominant clearance mechanism, which in turn depends
on particle dissolution rate influencing its appearance in
the molecular state. On a microscopic scale drug dissol-
ution is required for drug presentation through mucus
and airways fluid to the epithelium, ultimately reaching
the target receptor and supporting the desired thera-
peutic action. Dose numbers for the central airways can
be calculated assuming lung fluid volume in the central
airways to be 10–30 mL and a regional dose of 50 % of
total lung dose. Based on these calculations, low solubil-
ity inhaled corticosteroids and large dose anti-infective
agents may be dissolution limited. Inhaled corticoste-
roids with dose numbers greater than 10 have a mean
dissolution time greater than those with dissolution
numbers less than 1. The particle size of inhaled drugs
is, by necessity, much smaller than their oral coun-
terparts. Therefore, the main approach to tuning the
dissolution number is through formulation strategies.
Dissolution test methods are currently non-
standardized for inhaled drugs and are not intendedto provide IVIVC correlations. A common/standard-
ized dissolution test method would benefit formula-
tors for development purposes.
Local drug metabolism, the action of transporters, the
rate of absorption, and receptor binding, modulate the
duration of local action. The combined macro- and
microscopic mechanism of disposition dictate the
pharmacokinetics and overall pharmacodynamics and ef-
ficacy of the drug in the entire organ system. For locally
acting pulmonary drugs, systemic blood levels are a
measure of the drug in a compartment that is not asso-
ciated with the site of action. Therefore, kinetics is more
important than the overall extent of absorption.
The workshop concluded that unlike the GI, the
dissolution rate is a more significant measure of drug
availability in the lungs than solubility. The dose number
for currently marketed inhaled drugs identified only a
few solubility-limited compounds/classes and dissolution
number can be modified through formulation ap-
proaches. For local action, permeability or the rate of ab-
sorption may only be relevant as a predictor of local
residence time and, therefore, duration of effect since it
reflects drug that is removed from the target site, with
the notable exception of systemic disease therapy. Slow
dissolution rate and a low absorption number are more
favorable properties for locally-acting low molecular pul-
monary drugs since this increases the residence time in
the lung. This is counter to the giBCS model and dem-
onstrates that a more accurate predictive model would
require consideration of the other factors involved in
drug disposition including site of deposition and specific
clearance mechanisms and their rates of drug presenta-
tion to, and from, the intended target site.
The overall goal of this workshop was to determine
whether or not an inhalation product biopharmaceu-
tics classification system (iBCS) based on physico-
chemical properties of physiologic relevance could be
developed for pulmonary drug products. It was not to
develop the specific model or classification system. A
classification system, once fully developed, would be a
tool for the formulators and discovery chemists work-
ing in the pulmonary drug delivery field; it is not the
intent to use such a model to obtain regulatory relief.
From this perspective, it can be concluded that there
is an opportunity to develop a model to classify pul-
monary drugs based on physicochemical attributes
specific to lung physiology and drug delivery and
therefore the workshop met the intended goal.
Endnotes
1AAPS/FDA/USP Workshop: Inhalation Biopharma-
ceutical Product Classification System Development:
Challenges and Opportunities, Baltimore, MD. 2015
March 16-17.
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